This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Whilst drug resistance typically involves microbes chemically inactivating an antimicrobial drug or a cell mechanically stopping the uptake of a drug, another form of drug resistance can arise from the formation of biofilms. Some bacteria are able to form biofilms by adhering to surfaces on implanted devices such as catheters and prostheses and creating an extracellular matrix for other cells to adhere to. This provides them with a stable environment from which the bacteria can disperse and infect other parts of the host. Additionally, the extracellular matrix and dense outer layer of bacterial cells can protect the inner bacteria cells from antimicrobial drugs. Phage therapy is a technique that was discovered before antibiotics, but fell to the wayside as antibiotics became predominate. It is now being considered as a potential solution to increasing antimicrobial resistance. Bacteriophages, viruses that only infect bacteria, can specifically target the bacteria of interest and inject their genome. This process makes the bacteria halt its own production to make more phages, and this continues until the bacteria lyses itself and releases the phages into the surrounding environment. Phage therapy does not kill microbiota since it is specific, and it can help those with antibiotic allergies. Some drawbacks are that it is a time-intensive process since the specific bacterium needs to be identified. It also does not currently have the body of research supporting its effects and safety that antibiotics do.
== Industrial applications == Although the use of protecting groups is not preferred in industrial syntheses, they are still used in industrial contexts, e.g. sucralose (sweetener) or the Roche synthesis of oseltamivir (Tamiflu, an antiviral drug) An important example of industrial applications of protecting group theory is the synthesis of ascorbic acid (Vitamin C) à la Reichstein.
== Medical uses == Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder. Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of vilazodone over placebo were found. According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo. According to the US Food and Drug Administration (FDA) in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants." Development of vilazodone for generalized anxiety disorder has been stopped as of 2017. While there is tentative evidence of a small benefit in generalized anxiety disorder, there is a high rate of side effects.
Carol Beattie is appointed chief executive of the Scottish National Party after taking on the post in an acting role following the resignation of her predecessor, Murray Foote. 11 March – The Metropolitan Police launch an investigation into Rupert Lowe over allegations of making "verbal threats". The Democracy and Boundary Commission has decided that all Senedd seats will have Welsh language only names from 2026. Reform UK gains its first representative on Falkirk Council following the defection of ex-Conservative turned Independent councillor Claire Mackie-Brown. 12 March – Keir Starmer says the UK will "keep all options on the table" regarding Donald Trump's steel and aluminium tariffs. All 404 Labour MPs are summoned to Downing Street for a briefing on the spring statement. Former First Minister of Scotland, Nicola Sturgeon, announces she will stand down from the Scottish Parliament at the 2026 election. Health Secretary Wes Streeting calls for his former assistant Sam Gould to resign from Redbridge London Borough Council after he admitted to indecent exposure. The requirement for a High Court judge to approve applications is dropped by the bill committee of the Terminally Ill Adults (End of Life) Bill. South Kesteven councillor Rosemary Trollope-Bellew leaves Reform UK just 11 days after joining. 13 March – Keir Starmer announces that NHS England will be abolished in order to "cut bureaucracy". First Minister of Scotland John Swinney holds talks with Eric Trump, the son of US President Donald Trump, at Bute House.
Sources: en.wikipedia.org
Significant linkage was also detected in the pericentromeric region of chromosome 8, overlapping with one of the regions detected in the Hamer lab's previous genomewide study. The authors concluded, "Results, especially in the context of past studies, support the existence of genes on pericentromeric chromosome 8 and chromosome Xq28 influencing development of male sexual orientation." In 2019, a genome-wide association study of 493,001 individuals concluded that hundreds or thousands of genetic variants underlie same-sex sexual behavior in both sexes, but in contrast to linkage studies they found no excess of signal on Xq28 or the rest of the X chromosome. This study was questioned on account of its reliance on a dichotomous ever/never measure that lumped together predominantly heterosexual, bisexual and homosexual individuals, including those who only experimented once with a same-sex partner, possibly resulting in misleading associations to personality traits. Hamer said that the findings of the 2019 study do not reveal any biological pathways for sexual orientation, but stated he hoped it would be the first of many to come. Hamer's findings provoked extensive public reaction, often based on misunderstanding of the science, which led to his interest in explaining the data to a wide audience through a book written in collaboration with a journalist. A 2016 article "Sexual Orientation, Controversy, and Science" includes a review of molecular genetics studies related to sexuality, starting with Hamer's work.
North-West Europe 1944–45 Tobruk 1941 Benghazi Raid North Africa 1940–43 Landing in Sicily Sicily 1943 Termoli Valli di Comacchio Italy 1943–45 Greece 1944–45 Adriatic Middle East 1943–44 Falkland Islands 1982 Western Iraq Gulf 1991
All of the alkali metals except lithium and caesium have at least one naturally occurring radioisotope: sodium-22 and sodium-24 are trace radioisotopes produced cosmogenically, potassium-40 and rubidium-87 have very long half-lives and thus occur naturally, and all isotopes of francium are radioactive. Caesium was also thought to be radioactive in the early 20th century, although it has no naturally occurring radioisotopes. (Francium had not been discovered yet at that time.) The natural long-lived radioisotope of potassium, potassium-40, makes up about 0.012% of natural potassium, and thus natural potassium is weakly radioactive. This natural radioactivity became a basis for a mistaken claim of the discovery for element 87 (the next alkali metal after caesium) in 1925. Natural rubidium is similarly slightly radioactive, with 27.83% being the long-lived radioisotope rubidium-87. Caesium-137, with a half-life of 30.17 years, is one of the two principal medium-lived fission products, along with strontium-90, which are responsible for most of the radioactivity of spent nuclear fuel after several years of cooling, up to several hundred years after use. It constitutes most of the radioactivity still left from the Chernobyl accident. Caesium-137 undergoes high-energy beta decay and eventually becomes stable barium-137. It is a strong emitter of gamma radiation. Caesium-137 has a very low rate of neutron capture and cannot be feasibly disposed of in this way, but must be allowed to decay.
Until 13 July 2013, the import and sale of absinthe technically required a special permit, since "oil of wormwood, being an essential oil obtained from plants of the genus Artemisia, and preparations containing oil of wormwood" were listed as item 12A, Schedule 8, Regulation 5H of the Customs (Prohibited Imports) Regulations 1956 (Cth). These controls have now been repealed, and permission is no longer required.
Robert "Bob" Swanson (1947–1999) was an American venture capitalist who co-founded Genentech in 1976 with Herbert Boyer. Genentech is one of the leading biotechnology companies in the world. He was CEO of Genentech from 1976 to 1990, and chairman from 1990 to 1996. Swanson graduated from the Massachusetts Institute of Technology, where he was a member of the Sigma Chi fraternity. He completed a B.S. degree in Chemistry as well as a master's degree in Management from the MIT Sloan School of Management. Both degrees were conferred in 1970. He is regarded as an instrumental figure in launching the biotechnology revolution. The authors of the book, 1,000 Years, 1,000 People: Ranking the Men and Women Who Shaped the Millennium ranked Mr. Swanson number 612. Mr. Swanson was inducted into the Junior Achievement U. S. Business Hall of Fame in 2006. He received the 2000 Biotechnology Heritage Award posthumously with Herbert Boyer. On December 6, 1999, he succumbed to glioblastoma, a type of brain cancer, at the age of 52.
Sources: en.wikipedia.org
=== Discontinued === Acebilustat (CTX-4430; EP-501) – leukotriene A4 (LTA4H) hydrolase inhibitor Afamelanotide (CUV-1647; EPT-1647; Melanotan I; Melanotan; Prenumbra; Scenesse) – melanocortin receptor agonist BBI-3000 – retinoid X receptor agonist BMX-010 (MnTE-2-PyP) – reactive oxygen species (ROS) scavenger and radioprotector Botulinum toxin A liquid (AI-09) – acetylcholine release inhibitor and neuromuscular blocking agent Botulinum toxin A topical (ANT-1207) – acetylcholine release inhibitor and neuromuscular blocking agent Cioteronel (CPC-10997; Cyoctol; X-Andron) – antiandrogen (androgen receptor antagonist) Diroleuton (DGLA; DHLA; DS-107; RO-12-1989) – omega-6 fatty acid and anti-inflammatory DMVT-503 (RVT-503) – undefined mechanism of action DX-0385 – retinoic acid metabolism modulator Encapsulated tretinoin cream – retinoid (retinoic acid receptor agonist) Epristeride (Aipuliete; ONO-9302; SKF-105657) – 5α-reductase inhibitor Falecalcitriol (DSC-103; F6VD3; flocalcitriol; Fulstan; hexafluorocalcitriol; hexafluorovitamin D3; Hornel; SM-8000; ST-630) – vitamin D/calcitriol analogue Gevokizumab (S-78989; VPM-087; XMA-005.2) – monoclonal antibody against interleukin-1β Hypochlorous acid (PR-013; PR-022) – disinfectant and other actions Imsidolimab (ANB-019) – monoclonal antibody against the interleukin-36 receptor Incyclinide (chemically modified tetracycline 3; CMT-3; COL-3; Metastat) – chemically modified tetracycline and matrix metalloproteinase inhibitor (no antibiotic activity) Ingenol disoxate (LEO-43204) – undefined mechanism of action JNJ-10229570 – melanocortin MC5 receptor antagonist MDI-301 – undefined mechanism of action MK-434 (MK-0434) – 5α-reductase inhibitor MTCH-24 (Zilex; Zorex) – undefined mechanism of action PF-06423264 – acetyl-CoA carboxylase inhibitor PSK-3841 (HMR-3841; RU-58841) – antiandrogen (androgen receptor antagonist) Research programme: acne therapeutics - Praxis – undefined mechanism of action Research programme: tetracycline derivatives - Paratek Pharmaceuticals (P-004292) – tetracycline derivatives Rose bengal sodium (PH-10; Provecta; PV-10; rose bengal; Xantryl) – immunomodulator and other actions Santalum album ointment (albuterpenoid; East Indian sandalwood oil) – undefined mechanism of action Talarozole (R115866; Rambazole) – retinoic acid metabolism modulator Thykamine (PCT-233; PUR-0110) – undefined mechanism of action (anti-inflammatory) Valproic acid topical (Avugane; Baceca; G2M-777) – histone deacetylase inhibitor and other actions XEN-801 (XEN801) – stearoyl-CoA desaturase inhibitor XOMA-629 (XMP-629) – endotoxin inhibitor Zileuton (A-64077; Abbott-64077; ABT-077; CRTX-073; CTI-02; Zyflo) – 5-lipoxygenase inhibitor
Gamma irradiation is widely used due to its high penetration depth and dose uniformity, allowing for large-scale applications with high throughput. Additionally, gamma irradiation is significantly less expensive than using an X-ray source. In most designs, the radioisotope, contained in stainless steel pencils, is stored in a water-filled storage pool which absorbs the radiation energy when not in use. For treatment, the source is lifted out of the storage tank, and product contained in totes is passed around the pencils to achieve required processing. Treatment costs vary as a function of dose and facility usage. A pallet or tote is typically exposed for several minutes to hours depending on dose. Low-dose applications such as disinfestation of fruit range between US$0.01/lb and US$0.08/lb while higher-dose applications can cost as much as US$0.20/lb.
From the Cologne War through the Thirty Years' Wars (1618–1648), religious conflict devastated German lands and significantly reduced the population. The Peace of Westphalia ended religious warfare among the Imperial Estates. The legal system initiated by a series of Imperial Reforms (approximately 1495–1555) provided for considerable local autonomy and a stronger Imperial Diet. The House of Habsburg held the imperial crown from 1438 until the death of Charles VI in 1740. Following the War of the Austrian Succession and the Treaty of Aix-la-Chapelle, Charles VI's daughter Maria Theresa ruled as empress consort when her husband, Francis I, became emperor. From 1740, dualism between the Austrian Habsburg monarchy and the Kingdom of Prussia dominated German history. In 1772, 1793, and 1795, Prussia and Austria, along with the Russian Empire, agreed to the Partitions of Poland. During the period of the French Revolutionary Wars, the Napoleonic era and the subsequent final meeting of the Imperial Diet, most of the Free Imperial Cities were annexed by dynastic territories; the ecclesiastical territories were secularised and annexed. In 1806, the Imperium was dissolved; France, Russia, Prussia, and the Habsburgs (Austria) competed for hegemony in the German states during the Napoleonic Wars.
The dissection continues toward the brow and the glabella (the smooth prominence between the eyebrows) until the skin flap is sufficiently mobile to allow its relaxed transposition upon the nose. Under loupe magnification, the distal portion of the forehead flap is de-fatted, down to the subdermal plexus. Yet, the fat-removal should be conservative, especially if the patient is either a tobacco smoker or a diabetic, or both, because such health factors negatively affect blood circulation and tissue perfusion, and thus the timely and correct healing of the surgical scars to the nose. The flap is allowed to perfuse, while the donor site is sutured closed by means of the wide undermining deep to the frontalis muscle. At that time, diluted epinephrine can be injected to the forehead skin, but not to the area(s) near the pedicle of the forehead flap. Moreover, if the distal wound is wider than 25 mm, it usually is not closed by primary intention, with sutures, but is allowed to heal by secondary intention, by re-epithelialisation. The forehead flap is attached to the nasal wound with subcutaneous sutures and skin sutures. If the excess tension of a suture compromises the color of the skin flap, the suture can be loosened, with a skin hook, and observed for 10–15 minutes; if the skin color remains compromised (white), the suture is removed. Upon the complete attachment of the paramedian forehead flap to the nose, the surgical wounds are dressed only with antibiotic ointment. IV.
The two substrates of this enzyme are L-α-glycerophosphoric acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are dihydroxyacetonephosphoric acid, reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sn-glycerol-3-phosphate:NAD(P)+ 2-oxidoreductase. Other names in common use include L-glycerol-3-phosphate:NAD(P)+ oxidoreductase, glycerol phosphate dehydrogenase (nicotinamide adenine dinucleotide, (phosphate)), glycerol 3-phosphate dehydrogenase (NADP+), and glycerol-3-phosphate dehydrogenase [NAD(P)+]. This enzyme participates in glycerophospholipid metabolism.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.